Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Magini

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancers|March 11, 2023
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular CarcinomaLuca Ielasi, Francesco Tovoli, Matteo Tonnini, et al.
Current Oncology (Toronto, Ont.)|January 26, 2024
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic TherapyLuca Ielasi, Bernardo Stefanini, Fabio Conti, et al.
JHEP Reports : Innovation in Hepatology|March 22, 2021
NAFLD and MAFLD as emerging causes of HCC: A populational studyShuna Myers, Isabelle Neyroud-Caspar, Laurent Spahr, et al.
Molecular Ecology Resources|July 21, 2019
Integrating three comprehensive data sets shows that mitochondrial DNA variation is linked to species traits and paleogeographic events in European butterfliesLeonardo Dapporto, Alessandro Cini, Raluca Vodă, et al.
Scandinavian Journal of Gastroenterology|April 25, 2007
Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal functionAndrea Zambruni, Franco Trevisani, Veit Gülberg, et al.
Clinical and Translational Gastroenterology|January 14, 2021
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Clinical and Translational Gastroenterology|April 27, 2021
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Clinical Nuclear Medicine|November 7, 2009
C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenomaGiulia Magini, Mohsen Farsad, Marta Frigerio, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
The American Journal of Gastroenterology|February 23, 2007
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillanceFranco Trevisani, Giulia Magini, Valentina Santi, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancers|March 11, 2023
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular CarcinomaLuca Ielasi, Francesco Tovoli, Matteo Tonnini, et al.
Current Oncology (Toronto, Ont.)|January 26, 2024
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic TherapyLuca Ielasi, Bernardo Stefanini, Fabio Conti, et al.
JHEP Reports : Innovation in Hepatology|March 22, 2021
NAFLD and MAFLD as emerging causes of HCC: A populational studyShuna Myers, Isabelle Neyroud-Caspar, Laurent Spahr, et al.
Molecular Ecology Resources|July 21, 2019
Integrating three comprehensive data sets shows that mitochondrial DNA variation is linked to species traits and paleogeographic events in European butterfliesLeonardo Dapporto, Alessandro Cini, Raluca Vodă, et al.
Scandinavian Journal of Gastroenterology|April 25, 2007
Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal functionAndrea Zambruni, Franco Trevisani, Veit Gülberg, et al.
Clinical and Translational Gastroenterology|January 14, 2021
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Clinical and Translational Gastroenterology|April 27, 2021
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With SorafenibVito Sansone, Francesco Tovoli, Andrea Casadei-Gardini, et al.
Clinical Nuclear Medicine|November 7, 2009
C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenomaGiulia Magini, Mohsen Farsad, Marta Frigerio, et al.
Internal and Emergency Medicine|March 29, 2024
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenibBernardo Stefanini, Francesco Tovoli, Franco Trevisani, et al.
The American Journal of Gastroenterology|February 23, 2007
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillanceFranco Trevisani, Giulia Magini, Valentina Santi, et al.
Pageof 3